Trial for kidney damage in diabetes withdrawn before starting
NCT ID NCT06489340
Summary
This study aimed to test the safety and effectiveness of an experimental intravenous drug called VAR200 for adults with type 2 diabetes and kidney damage. The goal was to see if the drug could reduce the amount of protein leaking into the urine, a key sign of kidney injury, over a 12-week treatment period. The trial was withdrawn by the sponsor before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Advancement Center, PLLC
San Antonio, Texas, 78212, United States
Conditions
Explore the condition pages connected to this study.